NCT07374510尚未招募1 期
An Open-Label Combined Randomized, Blinded, Placebo- and Active-Controlled Phase Ia Clinical Trial: Evaluate the Safety and Immunogenicity of the Group ACYW135X Meningococcal Conjugate Vaccine in Individuals Aged 2 to 59 Years
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 150
- 主要终点
- Evaluate the safety of experimental vaccine among participants in different age groups (based on adverse reactions)
研究概览
简要总结
This trial adopts an open-label design combined with randomized, blinded, placebo-controlled and active-controlled design. The purpose of this trial is to evaluate the safety and immunogenicity of a Group ACYW135X Meningococcal Conjugate Vaccine. This study is planned to enroll 150 participants in total, with healthy individuals aged 2 to 59 years as participants. Among them, participants aged 18 to 59 years and 7 to 17 years will be assigned to the open-label design arm, while participants aged 4 to 6 years will be assigned to the randomized, blinded, placebo-controlled design arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 59 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy participants aged 2 to 59 years;
- •The participant and/or their legal guardian can understand and voluntarily sign the informed consent form (for participants aged 8 to 17 years, the form must be signed jointly by the participant and their legal guardian);
- •Be willing and able to comply with all visit schedules, sample collection procedures, vaccination protocols and other trial-related requirements, and maintain contact at any time during the study period;
- •Provide valid legal identification documents of the participant and/or their legal guardian;
- •Participants of childbearing potential and their sexual partners shall voluntarily adopt effective contraceptive measures from the date of signing the informed consent form until 3 months after the administration of the investigational vaccine, with no plans for sperm or egg donation during this period.
排除标准
- •History of meningococcal disease;
- •History of asthma; history of hypersensitivity to any vaccine or vaccine components (including serogroup A/C/Y/W135/X meningococcal capsular polysaccharide, mannitol, sucrose, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection), manifested as symptoms such as urticaria, dyspnea, or angioedema; or history of other severe adverse reactions following previous vaccination;
- •For children aged 2 to 6 years: history of previous vaccination with group ACYW135 meningococcal polysaccharide vaccine; or history of previous vaccination with any meningococcal conjugate vaccine other than group AC meningococcal conjugate vaccine; an interval of ≤ 12 months from the last dose of group A or group AC meningococcal polysaccharide vaccine or group AC meningococcal conjugate vaccine; history of vaccination with meningococcal conjugate vaccine since reaching 1 year of age. No vaccination history restrictions apply to participants aged 7 to 59 years;
- •Presence of autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);
- •Presence of coagulation disorders (e.g., coagulation factor deficiency, thrombocytopathy), or a history of significant bleeding, hematoma, or ecchymosis following previous intramuscular injection or venipuncture;
- •History of severe diseases or current diagnosis of severe chronic diseases (including but not limited to severe cardiovascular diseases, uncontrolled hypertension, hematological diseases, hepatic and renal diseases, gastrointestinal diseases, respiratory diseases, malignant tumors, and history of major organ transplantation);
- •Presence of severe congenital malformations, genetic defects, or malnutrition;
- •Presence or history of severe neurological diseases (epilepsy, convulsions, or seizures) or psychiatric disorders, or a family history of psychiatric disorders;
- •Chronic alcohol abuse [weekly alcohol consumption > 14 standard drinks (1 standard drink = 14 grams of 100% alcohol ≈ 360 mL beer, 150 mL wine, or 45 mL distilled spirits/liquor)] or a history of substance abuse (repeated and excessive use of narcotic drugs, psychotropic drugs, volatile organic solvents, etc.);
- •Receipt of immunosuppressive therapy or other immunomodulatory therapy for ≥ 14 days within the past 6 months (prednisone ≥ 20 mg/day or ≥ 2 mg/kg/day, or its equivalent dose); receipt of cytotoxic therapy; or planned receipt of such therapies during the study period;
- •Receipt of blood products within 3 months prior to the administration of the investigational vaccine;
- •Receipt of other investigational drugs or vaccines within 3 months prior to the administration of the investigational vaccine, or planned receipt of such drugs or vaccines during the study period;
- •Receipt of live attenuated vaccines or nucleic acid vaccines within the past 14 days, or receipt of subunit vaccines or inactivated vaccines within the past 7 days;
- •Participants who are breastfeeding, pregnant, or planning to become pregnant within 3 months after vaccination in this trial;
- •Presence of any acute diseases or acute exacerbation of chronic diseases within the past 7 days, or known or suspected active infections;
- •Clinically significant abnormal findings in laboratory tests：
- •Hematological parameters: white blood cell count, hemoglobin, platelet count;
- •Biochemical parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), blood glucose;
- •Urinalysis parameters: urine protein (PRO);
- •Axillary temperature > 37.0℃ prior to vaccination, or other vital sign measurements beyond the reference range;
- •Presence of skin damage, inflammation, ulceration, rash, or scarring at the intended injection site that may interfere with vaccination or observation of local reactions;
- •Any other factors that, in the investigator's judgment, render the participant unsuitable for participation in this clinical trial.
研究组 & 干预措施
placebo group
Placebo Comparator
2~6 years old
干预措施: Placebo (Biological)
high-dose experimental group
Experimental
2~59 years old
干预措施: high-dose Group ACYW135X Meningococcal Conjugate Vaccine (Biological)
medium-dose experimental group
Experimental
2~59 years old
干预措施: medium-dose Group ACYW135X Meningococcal Conjugate Vaccine (Biological)
low-dose experimental group
Experimental
2~6 years old
干预措施: low-dose Group ACYW135X Meningococcal Conjugate Vaccine (Biological)
active control group
Active Comparator
2~3 years old
干预措施: Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (Biological)
结局指标
主要结局
Evaluate the safety of experimental vaccine among participants in different age groups (based on adverse reactions)
时间窗: 30 days
The incidence rates of adverse reactions 30 days after vaccination
次要结局
- Evaluate the safety of experimental vaccine among participants in different age groups (based on AE and laboratory abnormalities)(30 days)
- Evaluate the safety of experimental vaccine among participants in different age groups (based on AE and laboratory abnormalities)(3 days)
- Evaluate the safety of experimental vaccine among participants in different age groups (based on AE and laboratory abnormalities)(6 months)
- Evaluate the immunogenicity of experimental vaccine among participants aged 2~6 years old(30 days)
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral RadiculopathyNeuropathic Pain From Lumbosacral RadiculopathyMedDRA version: 20.0 Level: LLT Classification code 10054095 Term: Neuropathic pain System Organ Class: 100000014315MedDRA version: 20.0 Level: PT Classification code 10050219 Term: Lumbar radiculopathy System Organ Class: 10029205 - Nervous system disordersEUCTR2015-004775-78-GBBiogen Idec Research Limited424
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MRI. Satunnaistettu, kaksoissokkoutettu ja lumekontrolloitu rinnakkaisryhmin etenevä tutkimus, jossa tutkitaan L-000124467 -lääkkeen kliinistä tehoa, turvallissuutta ja siedettävyyttä aaltomaista MS-tautia sairastavilla potilailla MRI menetelmällä. -Aaltomainen MS-tautiEUCTR2004-000073-64-FIMerck & Co., Inc./Suomen MSD Oy120
进行中（未招募）
1 期
A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 deficiency syndromeMedDRA version: 18.0Level: HLGTClassification code 10039911Term: Seizures (incl subtypes)System Organ Class: 10029205 - Nervous system disordersEUCTR2013-003771-35-FRltragenyx Pharmaceutical Inc80
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With SchizophreniaMedDRA version: 19.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2006-006434-17-ROJanssen-Cilag International N.V.644
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent,Versus Placebo in the Treatment of Post Herpetic NeuralgiaPost herpetic neuralgiaMedDRA version: 9.1Level: LLTClassification code 10036376Term: Post herpetic neuralgiaEUCTR2008-002108-24-DESolace Pharmaceuticals Inc.154